[HTML] frontiersin.org

[HTML][HTML] Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - frontiersin.org
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …
被引用次数：6 相关文章

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine.

S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - europepmc.org
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …
[HTML] nih.gov

[HTML][HTML] Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine

S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine.

S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - europepmc.org
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …